Resources
About Us
Home Report
Store
RWE Oncology Market
RWE Oncology Market by Component (Datasets [EHR, Claims, Cancer Registries], Consulting & Analytics Services), Application (Drug Development, Approval, Market Access, Post Market Surveillance), End User (Pharma, Payer, Provider) - Global Forecast to 2029
Report ID:MRHC - 104590 Pages: 200 Jul-2022 Formats*: PDF Category: Healthcare Delivery: 2 to 4 HoursThe RWE Oncology Market is expected to grow at a CAGR of 14.2% from 2022–2029 to reach $1.65 billion by 2029. Real-world evidence (RWE) is clinical evidence gathered via RWD analysis on the use and potential benefits or risks of a medical product. RWE can be produced through various study designs or analyses, including but not limited to randomized trials, large simple trials, pragmatic trials, and observational studies (prospective or retrospective). RWE has several applications in oncology, including drug development life cycles, reducing development duration, reducing the costs of clinical trials, and improving the probability of technical and regulatory success. The growth of this market is driven by factors such as the rising prevalence of cancer, rapidly growing big data in healthcare, the shift from volume to value-based care, and the rising focus on personalized healthcare.
Impact of COVID-19 on the RWE Oncology Market
The outbreak of the COVID-19 pandemic exerted a tremendous burden on healthcare sectors worldwide. The RWE oncology solutions market experienced an initial market shrinkage due to the impacts of the COVID-19 pandemic. The market shrinkage was attributed to factors such as the restrictions imposed on travel in several countries, the shifting of resources toward COVID-19 treatments in healthcare settings (including cancer care settings), and limited access to hospitals that disrupted the delivery of oncology services, including delayed diagnosis & treatment and clinical trial interruptions. These factors affected the amount of real-world data generated globally. The unavailability of treatment, patients, and resources significantly impacted the cancer care sector.
However, after the initial market shrinkage, real-world evidence (RWE) is set to become the most influential emerging technology in cancer care. The FDA recognized the challenges posed by the COVID-19 pandemic to oncology trials. In September 2021, it issued a draft guidance on real-world data for evidence generation supporting regulatory decisions. This initiative promoted the adoption of RWE in clinical trials, and since then, RWD has been used increasingly in cancer progression mapping and patient profiling, clinical trials, drug development, post-market studies, treatment choice, dosing strategies, treatment sequencing, adverse event management, regulatory decision making, and financial burden associated with oncology treatment.
Thus, the COVID-19 pandemic negatively impacted the RWE oncology solutions market. However, RWD made a significant impact during the COVID-19 pandemic and continues to play a significant role in the treatment of cancer due to the initiatives taken by the FDA to promote RWE and support regulatory decision-making for drugs and biological products.
Click here to : Request Sample of this Report
Key Findings in the RWE Oncology Market Study
Real-world Datasets Generated Larger Proportion of Revenue Compared to RWE Consulting & Analytics Services
In 2022, the real-world datasets segment is estimated to account for the larger share of the RWE oncology solutions market. The large market share of this segment is attributed to the growing amount of medical data generated in hospitals, increasing dependence on outcome-based studies on real-world data, and the rising demand for information regarding drug safety among payers, regulatory bodies, and providers.
Drug Development & Approvals Segment to Dominate the Market
In 2022, the drug development & approvals segment is estimated to account for the largest share of the RWE oncology solutions market. The large market share of this segment is attributed to the rising number of cancer cases, compelling pharmaceutical and biopharmaceutical companies to focus on drug development for cancer treatment. The effective deployment of RWE can significantly accelerate the pace of discovery, enable drug approvals, and help understand the impact of new oncology therapies, boosting the growth of this segment.
Pharmaceutical & Medical Device Companies Segment to Register Largest Share in the RWE Oncology Market by 2029
The pharmaceutical & medical device companies segment is estimated to account for the largest share of the RWE solutions market in 2022. The large market share of this segment is attributed to the importance of RWE studies in cancer drug development & approvals and the growing need to avoid costly drug recalls and assess drug performance in real-world settings.
North America to Dominate the Market
In 2022, North America is estimated to account for the largest share of the RWE oncology solutions market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The high market growth in North America is attributed to the increasing number of cancer cases, stringent regulations for drug approvals, implementation of the 21st Century Cures Act, increased usage of electronic datasets, advanced healthcare industry, and the rising amount of big data in healthcare.
Additionally, the adoption of EHRs in hospitals and patient registries is boosting the RWE oncology solutions market in North America. Basic EHR adoption has increased since 2010 in the U.S., from 27.9% in 2010 to nearly 86% in 2017. As of 2021, 94% of the hospitals in the U.S. are in the process of adopting EHRs.
Key Players
The report includes a competitive landscape based on an extensive assessment of the key strategic developments of leading market participants over the past four years. The key players profiled in the RWE oncology solutions market report include IQVIA Holdings Inc.(U.S.), ICON plc (Ireland), PPD, Inc. (U.S.), SYNEOS HEALTH, INC. (U.S.), CLARIVATE PLC (U.S.), Medpace Holdings Inc. (U.S.), Symphony Innovation, LLC (U.S.), Clinigen Group plc (U.K.), Cognizant Technology Solutions Corporation (U.S.), Oracle Corporation (U.S.), PAREXEL International Corporation (U.S.), PerkinElmer, Inc. (U.S.), SAS Institute Inc. (U.S.), UnitedHealth Group Incorporated (U.S.), and Flatiron Health (U.S.).
Scope of the Report:
RWE Oncology Solutions Market, by Component
- Real-world Datasets
- Disparate Datasets
- EMR/EHR/Clinical Data
- Claims & Billing Data
- Pharmacy Data
- Cancer Registries
- Other Disparate Datasets
- Integrated Datasets
- Disparate Datasets
- Real-world Consulting & Analytics Services
(Note: Other Disparate Datasets include data generated from mobile applications, wearable devices, and social media).
RWE Oncology Solutions Market, by Application
- Drug Development & Approvals
- Market Access & Reimbursement/Coverage Decisions
- Post-market Surveillance
- Medical Device Development & Approvals
- Other Applications
(Note: Other Applications include regulatory and clinical decision-making).
RWE Oncology Solutions Market, by End User
- Pharmaceutical, Biotechnology, and Medical Device Companies
- Healthcare Payers
- Healthcare Providers
- Other End Users
(Note: Other end users include academic research institutions, patient advocacy groups, regulators, and health technology assessment agencies).
RWE Oncology Solutions Market, by Geography
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe (RoE)
- Asia-Pacific (APAC)
- Japan
- China
- India
- South Korea
- Taiwan
- Singapore
- Rest of APAC (RoAPAC)
- Latin America
- Middle East & Africa
Key questions answered in the report:
The RWE oncology solutions market study covers the market sizes and forecasts for various real-world evidence oncology solutions offered by key market players. These solutions are utilized to support pharmaceutical, biotechnology & medical device companies, healthcare payers, healthcare providers, and other end users in making key decisions related to drug development & approvals, medical device development & approvals, market access & reimbursement/coverage decisions, post-market surveillance. The RWE oncology solutions market study provided in this report involves the value analysis of various segments and subsegments of RWE oncology solutions providers at the regional and country levels.
The global RWE oncology solutions market is projected to reach $1.65 billion by 2029, at a CAGR of 14.2% during the forecast period.
Based on component, in 2022, the real-world datasets segment is estimated to account for the larger share of the RWE oncology solutions market. The large market share of this segment is attributed to the growing amount of medical data generated in hospitals, increasing dependence on outcome-based studies on real-world data, and the rising demand for information regarding drug safety among payers, regulatory bodies, and providers.
Based on application, in 2022, the drug development & approvals segment is estimated to account for the largest share of the RWE oncology solutions market. The large market share of this segment is attributed to the rising number of cancer cases, compelling pharmaceutical and biopharmaceutical companies to focus on drug development for cancer treatment. The effective deployment of RWE can significantly accelerate the pace of discovery, enable drug approvals, and help understand the impact of new oncology therapies, boosting the growth of this segment.
The growth of this market is driven by factors such as the rising prevalence of cancer, rapidly growing big data in healthcare, the shift from volume to value-based care, and the rising focus on personalized healthcare. Furthermore, emerging markets, rising focus on end-to-end RWE services, and rising adoption of mobile applications and wearable devices and AI in RWE are expected to provide significant growth opportunities for market players and new entrants in this market.
The key companies operating in the RWE oncology solutions market include IQVIA Holdings Inc. (U.S.), ICON plc (Ireland), PPD, Inc. (U.S.), SYNEOS HEALTH, INC. (U.S.), CLARIVATE PLC (U.S.), Medpace Holdings Inc. (U.S.), Symphony Innovation, LLC (U.S.), Clinigen Group plc (U.K.), Cognizant Technology Solutions Corporation (U.S.), Oracle Corporation (U.S.), PAREXEL International Corporation (U.S.), PerkinElmer, Inc. (U.S.), SAS Institute Inc. (U.S.), UnitedHealth Group Incorporated (U.S.), and Flatiron Health (U.S.).
Emerging economies from Asia, such as Japan and China, are projected to offer significant growth opportunities for companies operating in this market. The increasing demand for data defining the value and effectiveness of medicines by payers, the high demand for conducting real-world studies in drug R&D, and increasing government interest in using real-world studies for regulatory decision-making are the factors expected to offer growth opportunities for market players in this region.
1. Introduction
1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency
2. Research Methodology
2.1. Research Process
2.2. Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research
2.3. Market Assessment
2.3.1. Market Size Estimation
2.3.1.1. Bottom-up Approach
2.3.1.2. Top-down Approach
2.3.1.3. Growth Forecast
2.3.2. Market Share Analysis
3. Executive Summary
4. Market Insights
4.1. Market Overview
4.2. Drivers
4.2.1. Growing Burden of Cancer
4.2.2. Rising Focus Towards Personalized Healthcare
4.2.3. Delays in Drug Development and the Subsequent Increase in Development Costs
4.2.4. Shift Towards Value-based Care
4.2.5. Rapidly Growing Big Data in Healthcare
4.3. Restraints
4.3.1. Reluctance to Rely on Real-world Studies
4.4. Opportunities
4.4.1. Emerging Economies
4.4.2. Rising Focus on End-to-end RWE Services
4.4.3. Rising Adoption of Wearable Devices, Mobile Apps, and Artificial Intelligence in RWE
4.5. Challenges
4.5.1. Lack of Standardized Methodologies to Develop RWE
4.6. Impact Assessment of COVID-19
4.7. Key Market Trends
4.7.1. Growing Adoption of RWE in Drug Development and Commercialization
4.7.2. Rising Number of Consolidations
4.7.3. Improved Patient Outcomes and value Creation from Real-world Evidence
5. Regulatory Analysis— Real-world Evidence (RWE) Oncology Solutions Market
5.1. Introduction
5.2. North America
5.3. Europe
5.4. Asia-Pacific
5.5. Rest of the World
6. Pricing Models (EMR/Genomic/Integrated Datasets)
6.1. Introduction
6.2. Pay Per Patient Record (Volume-based Pricing)
6.3. Pay Per Usage (Value-based Pricing)
6.4. Annual Subscription
7. Global RWE Oncology Solutions Market, by Component
7.1. Introduction
7.2. Datasets
7.2.1. Disparate Datasets
7.2.1.1. EMR/EHR/Clinical Data
7.2.1.2. Claims & Billing Data
7.2.1.3. Pharmacy Data
7.2.1.4. Cancer Registries
7.2.1.5. Other Disparate Datasets
7.2.2. Integrated Datasets
7.3. Consulting Services
8. Global RWE Oncology Solutions Market, by Application
8.1. Introduction
8.2. Drug Development & Approvals
8.3. Market Access & Reimbursement/Coverage Decisions
8.4. Medical Device Development & Approvals
8.5. Post-market Surveillance
8.6. Other Applications
9. Global RWE Oncology Solutions Market, by End User
9.1. Introduction
9.2. Pharmaceutical, Biotechnology, and Medical Device Companies
9.3. Healthcare Payers
9.4. Healthcare Providers
9.5. Other End Users
10. RWE Oncology Solutions Market, by Geography
10.1. Introduction
10.2. North America
10.2.1. U.S.
10.2.2. Canada
10.3. Europe
10.3.1. U.K.
10.3.2. Germany
10.3.3. France
10.3.4. Italy
10.3.5. Spain
10.4. Asia-Pacific
10.4.1. Japan
10.4.2. China
10.4.3. India
10.4.4. South Korea
10.4.5. Taiwan
10.4.6. Singapore
10.4.7. Rest of Asia-Pacific
10.5. Latin America
10.6. Middle East & Africa
11. Competitive Landscape
11.1. Introduction
11.2. Key Growth Strategies
11.3. Competitive Benchmarking
11.4. Market Share Analysis (2020)
11.4.1. IQVIA Holdings, Inc. (U.S.)
11.4.2. ICON plc (Ireland)
11.4.3. PPD, Inc.
12. Company Profiles
12.1. IQVIA HOLDINGS INC.
12.2. PPD, Inc.
12.3. ICON plc
12.4. Parexel International Corporation
12.5. IBM CORPORATION
12.6. UnitedHealth Group Incorporated
12.7. Flatiron Health
12.8. ORACLE CORPORATION
12.9. SAS Institute, Inc.
12.10. Anthem, Inc.
12.11. Clinigen Group plc
12.12. Cognizant Technology Solutions Corporation
12.13. PerkinElmer, Inc.
13. Appendix
13.1. Questionnaire
13.2. Available Customization
LIST OF TABLES
Table 1 Global RWE Oncology Solutions Market Drivers: Impact Analysis (2021–2028)
Table 2 Number of Persons Aged 65 Years or Over, by Region (2019 Vs. 2050)
Table 3 Total Per-study Cost (In USD Million), by Phase and Therapeutic Area
Table 4 Sources of Healthcare Data
Table 5 Global RWE Oncology Market Restraints: Impact Analysis (2021–2028)
Table 6 RWE in Latin American Countries
Table 7 Observed Indicative Prices of Real-World Data by Type (USD Per Patient Record)
Table 8 Global RWE Oncology Solutions Market Size, by Component, 2019–2029 (USD Million)
Table 9 Global Real-world Evidence Oncology Datasets Market Size, by Type, 2019–2029 (USD Million)
Table 10 Real-world Evidence Oncology Datasets Market Size, by Country/Region, 2019–2029 (USD Million)
Table 11 Global RWE Oncology Disparate Datasets Market Size, by Type, 2019–2029 (USD Million)
Table 12 RWE Oncology Disparate Datasets Market Size, by Country/Region, 2019–2029 (USD Million)
Table 13 RWE Oncology EMR/EHR/Clinical Data Market Size, by Country/Region, 2019–2029 (USD Million)
Table 14 RWE Oncology Claims & Billing Data Market Size, by Country/Region, 2019–2029 (USD Million)
Table 15 RWE Oncology Pharmacy Data Market Size, by Country/Region, 2019–2029 (USD Million)
Table 16 RWE Cancer Registries Data Market Size, by Country/Region, 2019–2029 (USD Million)
Table 17 Other RWE Oncology Disparate Datasets Market Size, by Country/Region, 2019–2029 (USD Million)
Table 18 RWE Oncology Integrated Datasets Market Size, by Country/Region, 2019–2029 (USD Million)
Table 19 RWE Oncology Consulting Services Market Size, by Country/Region, 2019–2029 (USD Million)
Table 20 Global RWE Oncology Solutions Market Size, by Application, 2019–2029 (USD Million)
Table 21 Global RWE Oncology Solutions Market Size for Market Access & Reimbursement/Coverage Decisions, by Country/Region, 2019–2029 (USD Million)
Table 22 Oncology: Drugs in the R&D Pipeline
Table 23 Global RWE Oncology Solutions Market Size for Drug Development & Approvals, by Country/Region, 2019–2029 (USD Million)
Table 24 Global RWE Oncology Solutions Market Size for Medical Device Development & Approvals, by Country/Region, 2019–2029 (USD Million)
Table 25 Global RWE Oncology Solutions Market Size for Post-Market Surveillance, by Country/ Region, 2019–2029 (USD Million)
Table 26 Global RWE Oncology Solutions Market Size for Other Applications, by Country/Region, 2019–2029 (USD Million)
Table 27 Global RWE Oncology Solutions Market Size, by End User, 2019–2029 (USD Million)
Table 28 Global RWE Oncology Solutions Market Size for Pharmaceutical, Biotechnology, and Medical Device Companies, by Country / Region, 2019–2029 (USD Million)
Table 29 Global RWE Oncology Market Size for Healthcare Payers, by Country/Region, 2019–2029 (USD Million)
Table 30 Global RWE Oncology Solutions Market Size for Healthcare Providers, by Country/Region, 2019–2029 (USD Million)
Table 31 Global RWE Oncology Market Size for Other End Users, by Country/Region, 2019–2029 (USD Million)
Table 32 Global RWE Oncology Solutions Market Size, by Country/Region, 2020–2029 (USD Million)
Table 33 North America: RWE Oncology Solutions Market Size, by Country, 2020–2029 (USD Million)
Table 34 North America: RWE Oncology Solutions Market Size, by Component, 2020–2029 (USD Million)
Table 35 North America: RWE Oncology Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 36 North America: RWE Oncology Disparate Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 37 North America: RWE Oncology Solutions Market Size, by Application, 2020–2029 (USD Million)
Table 38 North America: RWE Oncology Solutions Market Size, by End User, 2020–2029 (USD Million)
Table 39 U.S.: Estimated Number of New Cancer Cases (2021–2022)
Table 40 U.S.: RWE Oncology Solutions Market Size, by Component, 2020–2029 (USD Million)
Table 41 U.S.: RWE Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 42 U.S.: RWE Disparate Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 43 U.S.: RWE Oncology Solutions Market Size, by Application, 2020–2029 (USD Million)
Table 44 U.S.: RWE Solutions Market Size, by End User, 2020–2029 (USD Million)
Table 45 Canada: RWE Oncology Solutions Market Size, by Component, 2020–2029 (USD Million)
Table 46 Canada: RWE Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 47 Canada: RWE Disparate Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 48 Canada: RWE Oncology Solutions Market Size, by Application, 2020–2029 (USD Million)
Table 49 Canada: RWE Oncology Market Size, by End User, 2020–2029 (USD Million)
Table 50 Europe: RWE Oncology Solutions Market Size, by Country, 2019–2029 (USD Million)
Table 51 Europe: RWE Oncology Solutions Market Size, by Component, 2020–2029 (USD Million)
Table 52 Europe: RWE Oncology Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 53 Europe: RWE Oncology Solutions Disparate Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 54 Europe: RWE Oncology Solutions Market Size, by Application, 2020–2029 (USD Million)
Table 55 Europe: RWE Oncology Solutions Market Size, by End User, 2020–2029 (USD Million)
Table 56 U.K.: Conferences and Workshops on Real-world Evidence Solutions
Table 57 U.K.: RWE Oncology Solutions Market Size, by Component, 2020–2029 (USD Million)
Table 58 U.K.: RWE Oncology Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 59 U.K.: RWE Oncology Solutions Disparate Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 60 U.K.: RWE Oncology Solutions Market Size, by Application, 2020–2029 (USD Million)
Table 61 U.K.: RWE Oncology Solutions Market Size, by End User, 2020–2029 (USD Million)
Table 62 Conferences, Symposia, and Workshops in Germany
Table 63 Germany: RWE Oncology Solutions Market Size, by Component, 2020–2029 (USD Million)
Table 64 Germany: RWE Oncology Solutions Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 65 Germany: RWE Oncology Solutions Disparate Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 66 Germany: RWE Oncology Solutions Market Size, by Application, 2020–2029 (USD Million)
Table 67 Germany: RWE Oncology Solutions Market Size, by End User, 2020–2029 (USD Million)
Table 68 France: RWE Oncology Solutions Market Size, by Component, 2020–2029 (USD Million)
Table 69 France: RWE Oncology Solutions Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 70 France: RWE Oncology Solutions Disparate Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 71 France: RWE Oncology Solutions Market Size, by Application, 2020–2029 (USD Million)
Table 72 France: RWE Oncology Solutions Market Size, by End User, 2020–2029 (USD Million)
Table 73 Italy: RWE Oncology Solutions Market Size, by Component, 2020–2029 (USD Million)
Table 74 Italy: RWE Oncology Solutions Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 75 Italy: RWE Oncology Solutions Disparate Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 76 Italy: RWE Oncology Market Size, by Application, 2020–2029 (USD Million)
Table 77 Italy: RWE Oncology Solutions Market Size, by End User, 2020–2029 (USD Million)
Table 78 Spain: RWE Oncology Market Size, by Component, 2020–2029 (USD Million)
Table 79 Spain: RWE Oncology Solutions Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 80 Spain: RWE Oncology Solutions Disparate Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 81 Spain: RWE Oncology Solutions Market Size, by Application, 2020–2029 (USD Million)
Table 82 Spain: RWE Oncology Solutions Market Size, by End User, 2020–2029 (USD Million)
Table 83 RoE: RWE Oncology Solutions Market Size, by Component, 2020–2029 (USD Million)
Table 84 RoE: RWE Oncology Solutions Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 85 RoE: RWE Oncology Solutions Disparate Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 86 RoE: RWE Oncology Solutions Market Size, by Application, 2020–2029 (USD Million)
Table 87 RoE: RWE Oncology Solutions Market Size, by End User, 2020–2029 (USD Million)
Table 88 Latin America: RWE Oncology Solutions Market Size, by Component, 2020–2029 (USD Million)
Table 89 Latin America: RWE Oncology Solutions Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 90 Latin America: RWE Oncology Solutions Disparate Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 91 Latin America: RWE Oncology Solutions Market Size, by Application, 2020–2029 (USD Million)
Table 92 Latin America: RWE Oncology Solutions Market Size, by End User, 2020–2029 (USD Million)
Table 93 Middle East & Africa: RWE Oncology Solutions Market Size, by Component, 2020–2029 (USD Million)
Table 94 Middle East & Africa: RWE Oncology Solutions Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 95 Middle East & Africa: RWE Oncology Solutions Disparate Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 96 Middle East & Africa: RWE Oncology Solutions Market Size, by Application, 2020–2029 (USD Million)
Table 97 Middle East & Africa: RWE Oncology Solutions Market Size, by End User, 2020–2029 (USD Million)
Table 98 Recent Developments, by Company, 2018–2021
LIST OF FIGURES
Figure 1 Key Stakeholders
Figure 2 Research Process
Figure 3 Key Secondary Sources
Figure 4 Primary Research Techniques
Figure 5 Key Executives Interviewed
Figure 6 Breakdown of Primary Interviews (Supply-side & Demand-Side)
Figure 7 Market Size Estimation
Figure 8 Global RWE Oncology Solutions Market, by Component, 2022 Vs. 2029 (USD Million)
Figure 9 Global RWE Oncology Solutions Market, by Application, 2022 Vs. 2029 (USD Million)
Figure 10 Global RWE Oncology Solutions Market, by End User, 2022 Vs. 2029 (USD Million)
Figure 11 RWE Oncology Solutions Market, by Geography
Figure 12 Market Dynamics
Figure 13 Number of People with Chronic Conditions in the U.S. (2000-2030)
Figure 14 Percentage of Personalized Medicines Approved (2015-2020)
Figure 15 Asia-Pacific: Percent Share of Global Clinical Trial Activity (2012-2020)
Figure 16 Global RWE Oncology Solutions Market Size, by Component, 2022–2029 (USD Million)
Figure 17 U.S.: Number of E-Prescriptions, 2013–2020 (Billions)
Figure 18 Global RWE Oncology Solutions Market Size, by Application, 2022–2029 (USD Million)
Figure 19 Estimated Number of New Cancer Cases, by Region, 2020–2040 (In Millions)
Figure 20 Global RWE Oncology Solutions Market Size, by End User, 2022–2029 (USD Million)
Figure 21 Proportion of the Pharmaceutical Pipeline Which is in Development for Cancer, 2010–2021
Figure 22 Global RWE Oncology Solutions Market, by Region, 2022–2029 (USD Million)
Figure 23 North America: RWE Oncology Solutions Market Snapshot
Figure 24 Europe: RWE Oncology Solutions Market Snapshot
Figure 25 France: Share of Population Aged 65 & Above, 2010–2020
Figure 26 Italy: Share of Population Aged 65 Years & Above, 2015–2020
Figure 27 Key Growth Strategies Adopted by Leading Players (2018–2021)
Figure 28 Real-world Evidence Oncology Solutions: Competitive Benchmarking
Figure 29 Market Share Analysis: Real-world Evidence Oncology Solutions Industry (2021)
Figure 30 IQVIA HOLDINGS INC.: Financial Overview
Figure 31 PPD, Inc.: Financial Overview
Figure 32 ICON plc: Financial Overview
Figure 33 IBM corporation: Financial Overview
Figure 34 UnitedHealth Group Incorporated: Financial Overview
Figure 35 Oracle Corporation: Financial Overview
Figure 36 Anthem, Inc.: Financial Overview
Figure 37 Clinigen Group plc: Financial Overview
Figure 38 Cognizant Technology Solutions Corporation: Financial Overview
Figure 39 PerkinElmer, Inc.: Financial Overview
Author Name:
Proudly Partnering With Enterprises Around the Globe
Quick Contact
Related Reports
Oncology Information Systems Market - Global Opportunity Analysis and Industry Forecast (2024-2030)
Published Date: Jun-2024
Real-world Data (RWD) Market - Global Opportunity Analysis And Industry Forecast (2022-2029)
Published Date: Dec-2022
Oncology Ablation Market - Global Opportunity Analysis and Industry Forecast (2015-2020)
Published Date: Mar-2016
Infusion Pumps Market - Global Opportunity Analysis and Industry Forecast (2024-2030)
Published Date: Jul-2024
Microfluidic Immunoassay Market - Global Opportunity Analysis and Industry Forecast (2024-2031)
Published Date: Jan-2024
